Centiva Capital LP Invests $295,000 in Edwards Lifesciences Co. (NYSE:EW)

Centiva Capital LP bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 4,469 shares of the medical research company’s stock, valued at approximately $295,000.

Several other institutional investors also recently modified their holdings of EW. Lantz Financial LLC grew its position in shares of Edwards Lifesciences by 25.3% during the 2nd quarter. Lantz Financial LLC now owns 3,236 shares of the medical research company’s stock worth $299,000 after buying an additional 654 shares during the period. M&G Plc grew its position in shares of Edwards Lifesciences by 4.9% in the 2nd quarter. M&G Plc now owns 9,315 shares of the medical research company’s stock valued at $857,000 after purchasing an additional 431 shares during the period. ORG Partners LLC grew its position in shares of Edwards Lifesciences by 1,133.0% in the 2nd quarter. ORG Partners LLC now owns 1,159 shares of the medical research company’s stock valued at $105,000 after purchasing an additional 1,065 shares during the period. SteelPeak Wealth LLC grew its position in shares of Edwards Lifesciences by 7.3% in the 2nd quarter. SteelPeak Wealth LLC now owns 2,934 shares of the medical research company’s stock valued at $271,000 after purchasing an additional 199 shares during the period. Finally, AlphaMark Advisors LLC acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $1,730,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 3.5 %

Shares of Edwards Lifesciences stock opened at $73.41 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market capitalization of $43.29 billion, a price-to-earnings ratio of 10.59, a P/E/G ratio of 3.52 and a beta of 1.12. The business has a fifty day simple moving average of $68.75 and a two-hundred day simple moving average of $74.29. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.59 EPS. Research analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,262,521.36. This trade represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 35,000 shares of company stock worth $2,323,150 in the last 90 days. Company insiders own 1.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on EW. Evercore ISI decreased their price objective on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. JPMorgan Chase & Co. boosted their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Piper Sandler decreased their price objective on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Royal Bank of Canada boosted their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Thursday, December 5th. Finally, Oppenheimer restated an “outperform” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Seventeen research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $78.35.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.